A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01572610|
Recruitment Status : Terminated
First Posted : April 6, 2012
Last Update Posted : March 3, 2017
|Condition or disease||Intervention/treatment||Phase|
|Chronic Kidney Disease Type 2 Diabetes||Drug: RTA 402||Phase 2|
An exploratory study to investigate the effects of RTA 402 on glomerular filtration rate in CKD patients with type 2 diabetes mellitus.
To evaluate the safety of RTA 402.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 GFR Measuring Study of RTA 402 in CKD Patients With Type 2 Diabetes Mellitus|
|Actual Study Start Date :||February 2012|
|Actual Primary Completion Date :||November 2013|
|Actual Study Completion Date :||November 2013|
|Experimental: RTA 402||
Drug: RTA 402
once a day, oral administration
- Efficacy: glomerular filtration rate measured by inulin clearance [ Time Frame: Up to 16 weeks ]Individual subjects' change from baseline in GFR measured by inulin clearance will be evaluated.
- Adverse Event collection and assessment [ Time Frame: Up to 16 weeks ]Adverse Event collection
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01572610
|Koga city, Ibaraki, Japan|